Evelyn Partners Investment Management Services Ltd Sells 16,235 Shares of Zoetis Inc. $ZTS

Evelyn Partners Investment Management Services Ltd lessened its position in Zoetis Inc. (NYSE:ZTS) by 24.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 51,178 shares of the company’s stock after selling 16,235 shares during the period. Evelyn Partners Investment Management Services Ltd’s holdings in Zoetis were worth $6,050,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Prosperity Bancshares Inc bought a new stake in Zoetis during the fourth quarter valued at about $25,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Zoetis in the first quarter worth about $28,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis during the 4th quarter worth about $30,000. Elyxium Wealth LLC bought a new stake in Zoetis during the 4th quarter valued at approximately $32,000. Finally, Root Financial Partners LLC boosted its stake in Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. TD Cowen reduced their price target on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a report on Tuesday, June 30th. Citigroup lowered their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Morgan Stanley decreased their price objective on Zoetis from $115.00 to $99.00 and set an “overweight” rating on the stock in a report on Wednesday, July 22nd. HSBC lowered their price objective on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research report on Monday, July 6th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $118.33.

Insiders Place Their Bets

In other news, Director Paul Bisaro bought 2,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The stock was bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Frank A. Damelio bought 6,650 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were acquired at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders have bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by corporate insiders.

Zoetis Price Performance

Zoetis stock opened at $76.91 on Tuesday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The company has a market capitalization of $32.24 billion, a PE ratio of 12.75, a price-to-earnings-growth ratio of 1.18 and a beta of 0.75. Zoetis Inc. has a one year low of $71.47 and a one year high of $160.48. The business has a 50 day simple moving average of $77.27 and a 200 day simple moving average of $103.71.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion during the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter last year, the company earned $1.48 earnings per share. The business’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.87 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio is presently 35.16%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.